American Chinese science team has another breakthrough in liver cancer immunotherapy technology

October 20, 2015 Source: China News Network

Eureka Therapeutics, founded by American Chinese scientist Liu Cheng (later left third), has made new breakthroughs in the first targeted immunological T cell therapy for liver cancer. It is expected to enter clinical trials in the first half of 2016. The picture shows the main research team of Urek, the former right is the research leader Long Li.

Eureka Therapeutics, founded by Chinese scientists in the United States, has recently made breakthroughs in the targeted immunological T-cell therapy for liver cancer. It has been certified in multiple liver cancer models and multiple disease stages in experimental animals. It is expected to enter clinical trials in the largest cancer treatment center on the West Coast of the United States in the first half of 2016.

The head of the research team, Longli, introduced the latest progress to the reporter of the China News Service on the 16th. He pointed out that, first of all, a targeted immune T cell therapy needs to pass the test in the test animal before entering the clinical trial, which proves that the immune T cell can penetrate the multi-layer biological barrier after injection, reach the tumor site, and choose cancer cells. Sexually effective attacks.

Longli said that the first group of tests in Uric chose the human liver cancer model subcutaneously inoculated in mice. When the tumor grew subcutaneously in mice to a tumor that was 300 grams longer than the average person, the researchers injected the prepared immune T cells into the animal by intravenous or local intratumoral injection. The tumor growth rate was significantly slowed after intravenous injection. After local intratumoral injection, the tumor volume rapidly decreased, and 75% of the tumor disappeared after two weeks.

In another group of advanced liver cancer experiments, when the subcutaneous tumor grew to a tumor equivalent to 1.8 kg in the average person, the researchers began to inject the immune T cells into the tumor. After one week of single administration, the tumor growth rate was reduced by half compared with the control group. On the liver cancer model of abdominal metastasis, 80% of the mice were cured by intraperitoneal injection.

According to Longli, the core technology of Urek is different from the targeted immunotherapy methods that are now widely used in cancer patients. The researchers extracted a powerful killing immune cell called T cells from the patient's body and installed a navigational killing system that recognizes deep tumor markers of cancer cells. Once the modified immune cells are injected into the patient, they are injected into the patient. Can actively search for and continuously kill cancer cells, but does not harm normal tissues.

"This cell therapy technology combines the advantages of monoclonal antibodies, T-cell receptors, and CAR-T treatments to extend the treatment of highly therapeutic immune cells from blood-derived tumors to solid tumors," Long said.

Liu Cheng, founder of Uric, said that Uric is working with the largest cancer treatment center on the West Coast of the United States to conduct a clinical trial in the first half of next year.

Founded in 2006, Urek has started from three Chinese and has more than 30 multi-ethnic researchers to form a research and development team. At the same time, it has teamed up with a number of well-known cancer research institutions in the United States to cooperate with basic research and clinical trials.

Tof LiDAR Sensor

Tof(Time-of-flight), is JRT new product, which is a single-point LiDAR sensor. With a micro size of 46x17x7mm, customers can widely use in many Laser Measurement Solutions. The lidar distance sensor can measure 12m short-range. It's great for Unmanned Aerial Systems.Contact Us Now for data sheet.

ToF Sensor,Time of Flight Sensor,LiDAR Distance Sensor,ToF Distance Sensor

Chengdu JRT Meter Technology Co., Ltd , https://www.rangesensors.com